Treatment of chemotherapy-induced nausea and vomiting

被引：10
作者：
Inrhaoun H. [1 ]
Kullmann T. [2 ]
Elghissassi I. [1 ]
Mrabti H. [1 ]
Errihani H. [1 ]
机构：
[1] Department of Medical Oncology, National Institute of Oncology, Rabat
[2] Department of Medical Oncology, Saint Louis Hospital, Paris
来源：
Journal of Gastrointestinal Cancer | 2012年 / 43卷 / 4期
关键词：
Antiemetic; Chemotherapy; Nausea-vomiting;
D O I：
10.1007/s12029-012-9401-6
中图分类号：
学科分类号：
摘要：
Background: Recent improvements in medical oncology include both development of anticancer and supportive therapy. Serotonin receptor antagonists were introduced in clinical practice 20 years ago. Since then, the prevention and treatment of chemotherapy-induced nausea and vomiting allows continuing efficacious chemotherapy that earlier had to be stopped sometimes for intolerance. Aim: This anniversary review summarises the current antiemetic arsenal focussing on the most potent antiemetic drugs such as serotonin and substance P receptor antagonists. Result: Antiemetic treatment improves quality of life under chemotherapy and contributes to the survival benefit as well. In spite of the use of these new drugs, a significant number of patients still experience nausea and vomiting. Special complications like delayed emesis can be alleviated by combination therapies. Conclusion: Prevention and optimal management of chemotherapy-induced nausea and vomiting should be a goal for most patients receiving emetogenic chemotherapy. © 2012 Springer Science+Business Media, LLC.
引用
收藏
页码：541 / 546
页数：5
相关论文
共 43 条
  • [11] Réseau Oncolor Référenciels Anti-nauséeux et Anti-émétiques [En Ligne], (2003)
  • [12] Toth J., Szanto J., Magy Oncol, 52, 4, pp. 391-394, (2008)
  • [13] National Comprehensive Cancer Network: Antiemesis, Clinical Practice Guidelines in Oncology-v.1, (2010)
  • [14] Roila F., Hesketh P.J., Herrstedt J., Prevention of chemotherapy- and radiotherapy induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference, Ann Oncol, 17, pp. 20-28, (2006)
  • [15] Basch E., Prestrud A.A., Hesketh P.J., Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol, 29, 31, pp. 4189-4198, (2011)
  • [16] Hesketh P.J., Chemotherapy-induced nausea and vomiting, N Engl J Med, 358, pp. 2482-2494, (2008)
  • [17] Dewit R., Br J Cancer, 88, 12, pp. 1823-1827, (2003)
  • [18] Geling O., Eichler H., Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications, J Clin Oncol, 23, pp. 1289-1294, (2005)
  • [19] Lindley C., Blower P., Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis, Am J Health-Syst Pharm, 57, 18, pp. 1685-1697
  • [20] Kast R.E., European Journal of Cancer Care, 16, pp. 351-354, (2007)
12345